Cost–effectiveness analysis of endoscopic eradication therapy for treatment of high-grade dysplasia in Barrett’s esophagus
Abstract
Aim: The aim was to evaluate the cost–effectiveness of endoscopic eradication therapy (EET) with combined endoscopic mucosal resection and radiofrequency ablation for the treatment of high-grade dysplasia (HGD) arising in patients with Barrett’s esophagus compared with endoscopic surveillance alone in the UK. Materials & methods: The cost–effectiveness model consisted of a decision tree and modified Markov model. A lifetime time horizon was adopted with the perspective of the UK healthcare system. Results: The base case analysis estimates that EET for the treatment of HGD is cost-effective at a GB£20,000 cost–effectiveness threshold compared with providing surveillance alone for HGD patients (incremental cost–effectiveness ratio: GB£1272). Conclusion: EET is likely to be a cost-effective treatment strategy compared with surveillance alone in patients with HGD arising in Barrett’s esophagus in the UK.
Formats available
You can view the full content in the following formats:
References
Papers of special note have been highlighted as: • of interest
1.
Bhat S, Coleman HG, Yousef F et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J. Natl Cancer Inst. 103(13), 1049–1057 (2011).
2.
Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N. Engl. J. Med. 365(15), 1375–1383 (2011).
3.
Fitzgerald RC, di Pietro M, Ragunath K et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 63(1), 7–42 (2014).
4.
Corley DA, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss NS. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology 145(2), 312–319 e311 (2013).
5.
Fountoulakis A, Zafirellis KD, Dolan K, Dexter SP, Martin IG, Sue-Ling HM. Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer. Br. J. Surg. 91(8), 997–1003 (2004).
6.
Cooper GS, Yuan Z, Chak A, Rimm AA. Association of prediagnosis endoscopy with stage and survival in adenocarcinoma of the esophagus and gastric cardia. Cancer 95(1), 32–38 (2002).
7.
Kastelein F, van Olphen SH, Steyerberg EW, Spaander MC, Bruno MJ, ProBar-Study Group. Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression. Gut 65(4), 548–554 (2016).
8.
Oesophageal Cancer (C15), Age-Standardised One-, Five- and Ten-Year Net Survival, Adults (Aged 15–99), England and Wales, 2010–2011. www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/oesophageal-cancer/survival#A77uzhsT4OaPBkU5.99
9.
Buttar NS, Wang KK, Sebo TJ et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 120(7), 1630–1639 (2001).
10.
Montgomery E, Goldblum JR, Greenson JK et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum. Pathol. 32(4), 379–388 (2001).
11.
Fernando HC, Luketich JD, Buenaventura PO, Perry Y, Christie NA. Outcomes of minimally invasive esophagectomy (MIE) for high-grade dysplasia of the esophagus. Eur. J. Cardiothorac. Surg. 22(1), 1–6 (2002).
12.
Wang VS, Hornick JL, Sepulveda JA, Mauer R, Poneros JM. Low prevalence of submucosal invasive carcinoma at esophagectomy for high-grade dysplasia or intramucosal adenocarcinoma in Barrett's esophagus: a 20-year experience. Gastrointest. Endosc. 69(4), 777–783 (2009).
13.
Prasad GA, Wang KK, Buttar NS et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology 132(4), 1226–1233 (2007).
14.
Fernandez FG, Meyers BF. Quality of life after esophagectomy. Semin. Thorac. Cardiovasc. Surg. 16(2), 152–159 (2004).
15.
Palser TR, Cromwell DA, Hardwick RH et al. Re-organisation of oesophago-gastric cancer care in England: progress and remaining challenges. BMC Health Serv. Res. 9, 204 (2009).
16.
Drehmer M, Pereira MA, Schmidt MI et al. Associations of dairy intake with glycemia and insulinemia, independent of obesity, in Brazilian adults: the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Am. J. Clin. Nut. 101(4), 775–782 (2015).
17.
Shaheen NJ, Falk GW, Prasad GA, Gerson L. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am. J. Gastroenterol. 111(1), 30–50 (2015).
18.
American Gastroenterological A, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 140(3), 1084–1091 (2011).
19.
Haidry RJ, Dunn JM, Butt MA et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology 145(1), 87–95 (2013).
20.
Shaheen NJ, Sharma P, Overholt BF et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N. Engl. J. Med. 360(22), 2277–2288 (2009).
21.
Phoa KN, Pouw RE, Bisschops R et al. Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II). Gut 65(4), 555–562 (2016).
22.
Phoa KN, Pouw RE, van Vilsteren FG et al. Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology 145(1), 96–104 (2013).
23.
Developing NICE Guidelines: The Manual. (Eds.) National Institute for Health and Care Excellence, 2014) www.nice.org.uk/media/default/about/what-we-do/our-programmes/developing-nice-guidelines-the-manual.pdf
24.
Boger PC, Turner D, Roderick P, Patel P. A UK-based cost-utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barrett's oesophagus. Aliment. Pharmacol. Ther. 32(11–12), 1332–1342 (2010).
25.
Shaheen NJ, Inadomi JM, Overholt BF, Sharma P. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost–effectiveness analysis. Gut 53(12), 1736–1744 (2004).
26.
Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 136(7), 2101–2114 e2101–e2106 (2009).
27.
Das A, Wells C, Kim HJ, Fleischer DE, Crowell MD, Sharma VK. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus. Endoscopy 41(5), 400–408 (2009).
28.
Shaheen NJ, Overholt BF, Sampliner RE et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology 141(2), 460–468 (2011).
• This paper is of interest as the single landmark randomized controlled trial of 119 patients with Barrett's esophagus related neoplasia receiving radiofrequency ablation, the findings of which underpin the economic model.
29.
Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost–effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 33(8), 1872–1894 (2010).
30.
Givens DI. Dairy products: good or bad for cardiometabolic disease? Am.J. Clin. Nutr. 101(4), 695–696 (2015).
31.
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87(1), 4–14 (2010).
32.
Szende A, Janssen B, C J (Eds.). Self-reported population health: an international perspective based on EQ-5D. EuroQol. Springer (2014).
33.
Forouhi NG, Koulman A, Sharp SJ et al. Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident Type 2 diabetes: the EPIC-InterAct case-cohort study. Lancet Diabetes Endocrinol. 2(10), 810–818 (2014).
34.
Hur C, Choi SE, Rubenstein JH et al. The cost–effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology 143(3), 567–575 (2012).
35.
Haidry RJ, Butt MA, Dunn JM et al. Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry. Gut 64(8), 1192–1199 (2015).
Information & Authors
Information
Published In
Copyright
Rehan Haidry.
History
Published online: 25 May 2017
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Cost–effectiveness analysis of endoscopic eradication therapy for treatment of high-grade dysplasia in Barrett’s esophagus. (2017) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2016-0089
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Massimiliano di Pietro, Nigel J Trudgill, Melina Vasileiou, Gaius Longcroft-Wheaton, Alexander W Phillips, James Gossage, Philip V Kaye, Kieran G Foley, Tom Crosby, Sophie Nelson, Helen Griffiths, Muksitur Rahman, Gill Ritchie, Amy Crisp, Stephen Deed, John N Primrose, National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett’s oesophagus and stage I oesophageal adenocarcinoma, Gut, 10.1136/gutjnl-2023-331557, 73, 6, (897-909), (2024).
- Jin Lin Tan, Kingjin Heng, Mohamed Asif Chinnaratha, Norma B. Bulamu, Billingsley Kaambwa, Rajvinder Singh, Incidence rates of Barrett’s esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis, iGIE, 10.1016/j.igie.2024.01.001, 3, 1, (92-103.e3), (2024).
- Mark Nuijten, Livia Dainelli, Bahareh Rasouli, Krysmaru Araujo Torres, Moreno Perugini, Agnieszka Marczewska, A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer’s Perspective, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 10.2147/DMSO.S284855, Volume 14, (3147-3160), (2021).
- Joel H. Rubenstein, John M. Inadomi, Cost-Effectiveness of Screening, Surveillance, and Endoscopic Eradication Therapies for Managing the Burden of Esophageal Adenocarcinoma, Gastrointestinal Endoscopy Clinics of North America, 10.1016/j.giec.2020.08.005, 31, 1, (77-90), (2021).
- John J. McGoran, Krish Ragunath, Endoscopic management of Barrett's esophagus: Western perspective of current status and future prospects, Digestive Endoscopy, 10.1111/den.13812, 33, 5, (720-729), (2020).
- Prateek Sharma, Nicholas J. Shaheen, David Katzka, Jacques J.G.H.M. Bergman, AGA Clinical Practice Update on Endoscopic Treatment of Barrett’s Esophagus With Dysplasia and/or Early Cancer: Expert Review, Gastroenterology, 10.1053/j.gastro.2019.09.051, 158, 3, (760-769), (2020).
- Vicki Pollit, David Graham, Catherine Leonard, Alexandra Filby, Jessica McMaster, Stuart J. Mealing, Laurence B. Lovat, Rehan J. Haidry, A cost-effectiveness analysis of endoscopic eradication therapy for management of dysplasia arising in patients with Barrett’s oesophagus in the United Kingdom, Current Medical Research and Opinion, 10.1080/03007995.2018.1552407, 35, 5, (805-815), (2019).